Louis Navellier
Louis Navellier (RSS)
Editor, Blue Chip Growth

Louis Navellier is one of Wall Street's renowned growth investors. Providing investment advice to tens of thousands of investors for more than three decades, he has earned a reputation as a savvy stock picker and unrivaled portfolio manager.

Read complete bio
Recent Articles

3 Stocks to Buy That Will Keep You Safe

Nov. 7, 2014, 4:17 pm EST – Vasco Data Security International (VDSI), Strattec Security (STRT) and Federated National Holding (FNHC) are solid buys for any investor. More 

Buy CVS Health’s Strong Q3 Earnings

Nov. 7, 2014, 1:10 pm EST – CVS Health is a "strong buy" thanks to its excellent third-quarter earnings report as well as its strong institutional buying pressure. More 

DreamWorks – Better in the Box Office Than Your Portfolio

Nov. 7, 2014, 6:00 am EST – How to Train Your Dragon 2 isn't going to boost DreamWorks Animation (DWA) into "buy" territory. More 

2 Biotech Stocks to Buy After Earnings

Nov. 6, 2014, 11:45 am EST – Actavis (ACT) and Jazz Pharmaceuticals (JAZZ) reported outstanding Q3 earnings and are strong biotech stocks to buy. More 

3 Stocks to Buy That Will Keep You Safe

Nov. 6, 2014, 6:00 am EST – Vasco Data Security International (VDSI), Strattec Security (STRT) and Federated National Holding (FNHC) are solid buys for any investor. More 

SAVE: Join the Rally With Spirit Airlines

Nov. 5, 2014, 10:25 am EST – After the hit from Ebola and geopolitical tensions, lower fuel costs are helping to drive airlines stocks like Spirit Airlines (SAVE) back up. More 

XOM: Slow Your Roll on Exxon Mobil

Nov. 4, 2014, 11:45 am EST – Exxon Mobil's total revenues, while outperforming analysts' estimates, decreased by 4% to $107.48 billion, down from $112.37 billion the previous year. More 

3 Industry Leaders to Rely On

Nov. 4, 2014, 11:15 am EST – Hanesbrands, Marriott and Alcoa continue their upward trajectories and look like attractive buys for investors searching for solid returns. More 

2 Healthy Pharmaceutical Stocks to Buy

Nov. 4, 2014, 10:05 am EST – With earnings season winding down, here are two pharmaceutical companies that could boost the health of your portfolio. More 

EXPE: Book Big Returns With Expedia

Nov. 4, 2014, 6:00 am EST – Expedia's revenue growth was propelled by strong advertising and media revenue, and EXPE stock is a "strong buy" at the current price. More